Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest
ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.
How this was made
The 30-second read
Why it matters
Earnings beats across the group contrast with negative price moves for three firms, indicating market expectations were higher than disclosed guidance.
Market read
The earnings data offers fresh insight into revenue trends and market sentiment for the patient‑monitoring niche, useful for short‑term trading decisions.
What to watch
Regulatory environment and upcoming AI‑driven device innovations could materially affect future performance.
Background
The article provides a comparative Q2 earnings roundup for four patient‑monitoring companies, highlighting revenue growth, earnings beats, and stock reactions.
Ticker impact
ResMed reported Q2 revenue of $1.46B, up 8.6% YoY, with earnings beat but stock down 2.3% post‑earnings.
Potential short‑term pullback or flat performance.
Beat on EPS but market disappointment on revenue growth and guidance.
iRhythm posted Q2 revenue of $224.2M, up 20.1% YoY, beating estimates and raising full‑year guidance; stock down 13% post‑earnings.
Continued volatility; possible rebound if guidance holds.
Revenue beat and guidance raise contrast with sharp price decline.
Insulet reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates; revenue guidance missed, stock down 20.6% post‑earnings.
Further downside risk unless guidance improves.
Guidance miss outweighs earnings beat in market reaction.
DexCom posted Q2 revenue of $1.31B, up 13.1% YoY, beating estimates; full‑year guidance weakest among peers, stock up 12.3% post‑earnings.
Potential short‑term rally if guidance is not a concern.
Positive earnings surprise outweighs guidance weakness.
Market effects
Patient‑monitoring sector shows mixed earnings, highlighting revenue growth opportunities but pricing pressure.
U.S. healthcare equipment stocks may see heightened volatility following the earnings batch.
Results underscore broader trends in chronic‑disease management and digital health adoption.
Counterpoint
Despite earnings beats, the steep price declines suggest the market may be over‑reacting; upside potential remains.
Key entities
- CompanyResMed
Sleep‑apnea and respiratory device maker.
- CompanyiRhythm Technologies
Wearable cardiac monitoring provider.
- CompanyInsulet
Insulin‑delivery system manufacturer.
- CompanyDexCom
Continuous glucose monitoring leader.
